PKI has some exciting news>
PerkinElmer Awarded U.S. Patent for Industry-Leading Microarray Innovation
BOSTON--(BW HealthWire)--April 29, 2002--PerkinElmer, Inc. (NYSE: PKI - news), a leading provider of drug discovery, life science research and genetic disease screening solutions, today announced that the U.S. Patent and Trademark Office has issued the Company patent number 6,355,934 for all claims relating to an "Imaging System for an Optical Scanner." This patent covers the use of the Company's geometric beamsplitter, an integral component of the optical design for PerkinElmer Life Sciences' ScanArray® Express fluorescence scanning system. This laser scanner technology offers wavelength flexibility, ensuring upgradeability and application flexibility unmatched by other scanning technologies in the industry. With this patent, PerkinElmer Life Sciences continues to solidify its leadership position in microarray scanning technology.
All scanning-laser microarray scanners require a beamsplitter that causes the excitation beam to be directed to the sample while allowing the fluorescence beam to travel toward the detector. The fundamental design of PerkinElmer Life Sciences' patented geometric beamsplitter allows for efficient light delivery and collection for many wavelengths and delivers signal-to-noise ratio that is five times higher than traditional designs.
"The ScanArray Express is the cornerstone of PerkinElmer Life Sciences' microarray instrumentation platform, and this patent preserves our ability to provide customers with the industry's leading signal-to-noise performance and wavelength flexibility," said Dr. Neil Cook, vice president, Global Research & Development, and chief scientific officer, PerkinElmer Life Sciences. "Innovations such as the beamsplitter have enabled PerkinElmer Life Sciences to maintain the industry-leading position in microarray imaging since its inception."
VISG taking on water, as you predicted... |
